- Report
- December 2023
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- March 2023
- 143 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- January 2022
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- August 2022
Global
From €764EUR$790USD£656GBP
- Drug Pipelines
- June 2020
- 80 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- May 2023
- 101 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- December 2022
- 50 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- May 2022
- 45 Pages
Global
From €1934EUR$2,000USD£1,661GBP
The Hyperphosphatemia Drug market within the context of Hematological Drugs is a specialized market that focuses on the treatment of high levels of phosphate in the blood. Hyperphosphatemia is a condition that can be caused by a variety of medical conditions, including kidney disease, certain types of cancer, and certain medications. Treatment of hyperphosphatemia typically involves the use of drugs that bind to phosphate in the blood and prevent it from being absorbed by the body. These drugs are typically administered orally or intravenously, depending on the severity of the condition.
The Hyperphosphatemia Drug market is a highly competitive market, with a number of companies offering a variety of drugs to treat the condition. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
